-
Intravenous NPA for the treatment of infarcting myocardium early : in TIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarctionThe In Time-II InvestigatorsAims: To compare the efficacy and safety of lanoteplase, a single-bolus thrombolytic drug derived from alteplase tissue plasminogen activator, with the established accelerated alteplase regimen in ... patients presenting within 6 h of onset of ST elevation acute myocardial infarction. Methods and results: 15,078 patients were recruited from 855 hospitals worldwide and randomized in a 2:1 ratio to receive either lanoteplase 120 KU. kg(-1)as a single intravenous bolus, or up to 100 mg accelerated alteplase given over 90 min. The primary end-point was all-cause mortality at 30 days and the hypothesis was that the two treatments would be equivalent. By 30 days, 6.61% of alteplase-treated patients and 6.75% lanoteplase-treated patients had died (relative risk 1.02). Total stroke occurred in 1.53% alteplase- and 1.87% lanoteplase-treated patients (ns); haemorrhagic stroke rates were 0.64% alteplase and 1.12% lanoteplase (P=0.004). The net clinical deficit of 30-day death or non-fatal disabling stroke was 7.0% and 7.2%, respectively. By 6 months, 8.8% of alteplase-treated patients and 8.7% of lanoteplase-treated patients had died. Conclusion: Single-bolus weight-adjusted lanoteplase is an effective thrombolytic agent, equivalent to alteplase in terms of its impact on survival and with a comparable risk-benefit profile. The single-bolus regimen should shorten symptoms to treatment times and be especially convenient for emergency department or out-of-hospital administration. Copyright 2000 The European Society of Cardiology.Vir: European heart journal. - ISSN 0195-668X (Letn. 21, št. 24, 2000, str. 2005-2013)Vrsta gradiva - članek, sestavni del ; neleposlovje za odrasleLeto - 2000Jezik - angleškiCOBISS.SI-ID - 13581785
Avtor
Drinovec, Igor |
Horvat, Matija, 1935-2014 |
Krivec, Bojan |
Markež, J... |
Parežnik, Roman |
Pehnec, Zlatko |
Resman, J... |
Šifrer, Franc, dr. med., spec., 1960- |
Skale, Rafael |
Trinkaus, Darinka |
Voga, Gorazd |
The In Time-II Investigators
Teme
Myocardial infarction |
Drug therapy |
Physiopathology |
Fibrinolytic agents |
Therapeutic use |
Administration and dosage |
Middle age |
Aged |
Cerebrovascular disorders |
Epidemiology |
Etiology |
Double-blind method |
Infusions, intravenous |
Cerebral hemorrhage |
Etiology |
Epidemiology |
Risk factors |
Survival analysis
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|---|
Drinovec, Igor | 09157 |
Horvat, Matija, 1935-2014 | 01531 |
Krivec, Bojan | 20732 |
Parežnik, Roman | 20735 |
Pehnec, Zlatko | 24592 |
Šifrer, Franc, dr. med., spec., 1960- | |
Skale, Rafael | 21803 |
Trinkaus, Darinka | 26304 |
Voga, Gorazd | 14132 |
Izberite prevzemno mesto:
Prevzem gradiva po pošti
Obvestilo
Gesla v Splošnem geslovniku COBISS
Izbira mesta prevzema
Mesto prevzema | Status gradiva | Rezervacija |
---|
Prosimo, počakajte trenutek.